Nature Publication Describes First Example of a Clinically Applicable and Systemic mRNA Cancer Immunotherapy Vaccine

Nachrichtenquelle: PR Newswire (engl.)
01.06.2016, 19:07  |  1348   |   |   

MAINZ, Germany, June 1, 2016 /PRNewswire/ --

- Major Step Towards Truly Personalized Treatment of any Cancer 

- Elegantly Simple, Charge-adjusted RNA Lipid Complexes are Easy to Manufacture and can be Systemically and Easily Administered to Effectively Target Dendritic Cells in Key Organs

- Avoids Need to Engineer Complex Targeting Ligands

- Rapidly Stimulates Highly Potent Innate and Adaptive Immune Response Akin to Anti-viral Defense in Both Pre-clinical Tumor Models and Early Human Studies

- Any Peptide-based Antigen or Epitope can be Encoded as RNA Making This Type of Immunotherapy Applicable to all Cancer Types

BioNTech AG, a fully integrated biotechnology company developing individualized cancer immunotherapies, together with its translational research partner institute TRON, announces a publication in the internationally renowned scientific journal Nature, describing the first example worldwide of a clinically relevant and systemic mRNA cancer immunotherapy. The study entitled "Systemic RNA delivery to dendritic cells exploits antiviral defense for cancer immunotherapy" can be found here:

The paper outlines a novel and elegantly simple approach to target a nanoparticle mRNA vaccine (RNA-LPX) body-wide to dendritic cells in the spleen, lymph nodes and bone marrow, where a highly potent, dual-mechanism immune response mimicking a natural antiviral immune response is rapidly elicited. The dual mechanism involves both adaptive (T-cell-mediated) and innate (type-I interferon (IFN)-mediated) immune responses, with the IFN response being essential for full anti-tumor effects of the vaccines.

Professor Dr. Ugur Sahin, CEO of BioNTech AG, commented: "Our study introduces a novel class of extraordinarily potent cancer vaccines that enables efficient redirection of the immune system against a wide range of tumor antigens. This is a major step towards our aim to make truly personalized cancer immunotherapies available and applicable to all cancer types."

The publication presents new findings from the interdisciplinary collaboration between scientific and clinical teams at BioNTech AG, TRON, Research Center for Immunotherapy (FZI) and partners at the University Medical Center at the Johannes Gutenberg University Mainz and the Heidelberg University Hospital. The Group has pioneered individually tailored mRNA cancer vaccines and aims to progress clinical development to provide cancer patients and their treating physicians with new therapy options.

Seite 1 von 2

Diesen Artikel teilen

0 Kommentare

Schreibe Deinen Kommentar

Bitte melden Sie sich an, um zu kommentieren. Anmelden | Registrieren



Meistgelesene Nachrichten des Autors